Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9342816 | 0.97 | CYP2C19 (0.65) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL125690 | 0.97 | CYP2C19 (0.65) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL9183856 | 0.82 | CYP2C19 (0.61) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL2277073 | 0.80 | CYP2C19 (0.58) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL9183557 | 0.80 | CYP2C19 (0.65) | CYP2C19MMETBXAS1FFAR3USP2 | |
| SCHEMBL9180415 | 0.80 | CYP2C19 (0.65) | CYP2C19MMETBXAS1FFAR3USP2 | |
| SCHEMBL18235 | 0.78 | CYP2C19 (0.62) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL3636207 | 0.78 | CYP2C19 (0.56) | CYP2C19MMETBXAS1FFAR3AKR1C1 | |
| SCHEMBL1821191 | 0.78 | CYP2C19 (0.56) | CYP2C19MMETBXAS1USP2ALDH1A1 | |
| SCHEMBL17791681 | 0.78 | CYP2C19 (0.56) | CYP2C19MMETBXAS1FFAR3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528890-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011092611-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-5301087-A | Electrolyte for electrolytic capacitor and electrolytic capacitor using the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| EP-0501439-A1 | Electrolyte for electrolytic capacitor and electrolytic capacitor using the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | CYP2C19 856/4885MME 369/4885TBXAS1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.